Literature DB >> 25348625

Epitope specificity delimits the functional capabilities of vaccine-induced CD8 T cell populations.

Brenna J Hill1, Patricia A Darrah1, Zachary Ende1, David R Ambrozak1, Kylie M Quinn1, Sam Darko1, Emma Gostick2, Linda Wooldridge3, Hugo A van den Berg4, Vanessa Venturi5, Martin Larsen6, Miles P Davenport5, Robert A Seder1, David A Price7, Daniel C Douek8.   

Abstract

Despite progress toward understanding the correlates of protective T cell immunity in HIV infection, the optimal approach to Ag delivery by vaccination remains uncertain. We characterized two immunodominant CD8 T cell populations generated in response to immunization of BALB/c mice with a replication-deficient adenovirus serotype 5 vector expressing the HIV-derived Gag and Pol proteins at equivalent levels. The Gag-AI9/H-2K(d) epitope elicited high-avidity CD8 T cell populations with architecturally diverse clonotypic repertoires that displayed potent lytic activity in vivo. In contrast, the Pol-LI9/H-2D(d) epitope elicited motif-constrained CD8 T cell repertoires that displayed lower levels of physical avidity and lytic activity despite equivalent measures of overall clonality. Although low-dose vaccination enhanced the functional profiles of both epitope-specific CD8 T cell populations, greater polyfunctionality was apparent within the Pol-LI9/H-2D(d) specificity. Higher proportions of central memory-like cells were present after low-dose vaccination and at later time points. However, there were no noteworthy phenotypic differences between epitope-specific CD8 T cell populations across vaccine doses or time points. Collectively, these data indicate that the functional and phenotypic properties of vaccine-induced CD8 T cell populations are sensitive to dose manipulation, yet constrained by epitope specificity in a clonotype-dependent manner.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25348625      PMCID: PMC4238745          DOI: 10.4049/jimmunol.1401017

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  81 in total

Review 1.  Mapping T cell epitopes by flow cytometry.

Authors:  Bodo Hoffmeister; Felix Kiecker; Lydia Tesfa; Hans-Dieter Volk; Louis J Picker; Florian Kern
Journal:  Methods       Date:  2003-03       Impact factor: 3.608

2.  P-glycoprotein plays an insignificant role in the presentation of antigenic peptides to CD8+ T cells.

Authors:  G Russ; M Ramachandra; C A Hrycyna; M M Gottesman; I Pastan; J R Bennink; J W Yewdell
Journal:  Cancer Res       Date:  1998-10-15       Impact factor: 12.701

3.  Suppression of HIV replication by lymphoid tissue CD8+ cells correlates with the clinical state of HIV-infected individuals.

Authors:  D J Blackbourn; C E Mackewicz; E Barker; T K Hunt; B Herndier; A T Haase; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

4.  HIV-1 p24 Gag-specific cytotoxic T-lymphocyte responses in mice.

Authors:  B Doe; C M Walker
Journal:  AIDS       Date:  1996-06       Impact factor: 4.177

Review 5.  CD8 T cell responses to infectious pathogens.

Authors:  Phillip Wong; Eric G Pamer
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

6.  Class I MHC molecule-mediated inhibition of Sindbis virus replication.

Authors:  Y S Hahn; A Guanzon; C M Rice; C S Hahn
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

7.  IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs.

Authors:  Mehdi Yousfi Monod; Véronique Giudicelli; Denys Chaume; Marie-Paule Lefranc
Journal:  Bioinformatics       Date:  2004-08-04       Impact factor: 6.937

8.  Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load.

Authors:  M M Addo; X G Yu; A Rathod; D Cohen; R L Eldridge; D Strick; M N Johnston; C Corcoran; A G Wurcel; C A Fitzpatrick; M E Feeney; W R Rodriguez; N Basgoz; R Draenert; David R Stone; C Brander; P J R Goulder; E S Rosenberg; M Altfeld; B D Walker
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication.

Authors:  Christoph Hess; Marcus Altfeld; Seddon Y Thomas; Marylyn M Addo; Eric S Rosenberg; Todd M Allen; Rika Draenert; Robert L Eldrige; Jan van Lunzen; Hans-J Stellbrink; Bruce D Walker; Andrew D Luster
Journal:  Lancet       Date:  2004-03-13       Impact factor: 79.321

10.  Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells.

Authors:  Petra Wolint; Michael R Betts; Richard A Koup; Annette Oxenius
Journal:  J Exp Med       Date:  2004-03-29       Impact factor: 14.307

View more
  5 in total

1.  DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers.

Authors:  Madhura Mukhopadhyay; Moran Galperin; Mandar Patgaonkar; Sandhya Vasan; David D Ho; Alexandre Nouël; Mathieu Claireaux; Daniela Benati; Olivier Lambotte; Yaoxing Huang; Lisa A Chakrabarti
Journal:  J Immunol       Date:  2017-10-09       Impact factor: 5.422

2.  The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity.

Authors:  Ludmila Danilova; Valsamo Anagnostou; Franck Housseau; Kellie N Smith; Justina X Caushi; John-William Sidhom; Haidan Guo; Hok Yee Chan; Prerna Suri; Ada Tam; Jiajia Zhang; Margueritta El Asmar; Kristen A Marrone; Jarushka Naidoo; Julie R Brahmer; Patrick M Forde; Alexander S Baras; Leslie Cope; Victor E Velculescu; Drew M Pardoll
Journal:  Cancer Immunol Res       Date:  2018-06-12       Impact factor: 11.151

3.  Transient IL-10 receptor blockade can enhance CD8(+) T cell responses to a simian adenovirus-vectored HIV-1 conserved region immunogen.

Authors:  Genevieve Clutton; Anne Bridgeman; Arturo Reyes-Sandoval; Tomas Hanke; Lucy Dorrell
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  T Cell Receptor Profiling in Type 1 Diabetes.

Authors:  Laura M Jacobsen; Amanda Posgai; Howard R Seay; Michael J Haller; Todd M Brusko
Journal:  Curr Diab Rep       Date:  2017-10-11       Impact factor: 4.810

5.  Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial.

Authors:  Fabien Zoulim; Claire Fournier; François Habersetzer; Martin Sprinzl; Stanislas Pol; Carla S Coffin; Vincent Leroy; Mang Ma; Heiner Wedemeyer; Ansgar W Lohse; Robert Thimme; Karine Lugardon; Perrine Martin; Bérangère Bastien; Benoit Sansas; Nathalie Adda; Celine Halluard; Kaïdre Bendjama; Maud Brandely; Geneviève Inchauspé
Journal:  Hum Vaccin Immunother       Date:  2019-10-04       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.